Clinical Trial

A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells. This is a clinical study to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).
Protocol Amendment History 3 changes
notable Trial sites expanded: 1 -> 12 locations 2026-07-30
notable Primary completion pushed: 2025-06 -> 2026-10 2026-07-30
minor Completion pushed: 2026-12 -> 2027-06 2026-07-30
Trial Details
NCT Number NCT06413953
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Advanced Cancers
Enrollment 140 participants
Start Date 2024-06-27
Primary Completion 2026-10 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-29